Relative Retinal Blood Flow: A Novel and Informative Measure of Unilateral Retinal Vein Occlusion Severity

Rachelle Koch\(^1\), Brendan Seto\(^1\), Keiko Yamada\(^1\), Purva Atreay\(^1\), Colin A. Lemire\(^1\), Nina Hazra\(^1\), and Jorge G. Arroyo\(^1\)

\(^1\) Division of Ophthalmology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA

Citation: Koch R, Seto B, Yamada K, Atreay P, Lemire CA, Hazra N, Arroyo JG. Relative retinal blood flow: A novel and informative measure of unilateral retinal vein occlusion severity. Trans Vis Sci Tech. 2021;10(3):15, https://doi.org/10.1167/tvst.10.3.15

**Introduction**

Retinal vein occlusion (RVO) is second in prevalence to diabetic retinopathy among retinal diseases. In 2015, an estimated 28 million people were affected by RVO globally.\(^1\) RVOs are divided into two subtypes based on the location of the occlusion and severity of symptoms. Central retinal vein occlusion (CRVO) affect the central retinal vein at or near the lamina cribrosa, whereas branch retinal vein occlusion (BRVO) generally affects smaller venules at arteriovenous crossings.\(^2\)

The symptoms of CRVO are more severe than BRVO, but both initially manifest as a painless loss of vision usually caused by occlusion-related macular edema.\(^3\) Diagnosis of RVO is primarily accomplished by a convergence of clinical evidence from fundoscopy, fluorescein angiography, and optical coherence tomography (OCT).\(^2\) These methods focus primarily on the identification of signs such as tortuosity of retinal vessels, presence of macular edema, and areas of retinal nonperfusion. Recently, imaging techniques such as laser speckle flowgraphy (LSFG) and OCT angiography (OCTA) have emerged as more-precise and less-invasive ways of determining changes in retinal blood flow.\(^4,5\)

LSFG, approved by the Food and Drug Administration in 2016, is a relatively new, noninvasive technology for measuring retinal blood flow.\(^6–9\) Although other imaging techniques exist, such as...
blue-field simulation, spectral-domain OCT, laser Doppler flowmetry, laser Doppler velocimetry, Doppler Fourier-domain OCT, and swept source OCT. LSFG is unique in that it is a noninvasive technique that allows for quantitative, dynamic imaging of blood flow through retinal vessels and the choroid in the optic nerve head (ONH) and macula. OCTA is another new technology that quantitatively characterizes all layers of retinal vasculature. When compared to LSFG, however, OCTA appears to have issues with limited field of view and lower internal consistency.

LSFG metrics correspond well with our current understanding of retinal blood flow, both in patients with RVO and healthy subjects. Mean blur rate (MBR), a quantitative measure of erythrocyte movement based on laser speckle patterns, is the main output of LSFG, and most studies use MBR or a ratio of MBR as a direct correlate of blood flow. In RVO eyes, there is a significant association between vascular MBR and early- and late-phase fluorescein angiography circulation times. Similarly, two studies found a significantly lower blood flow in the ONH in ischemic RVO compared to nonischemic RVO, matching our understanding of severe perfusion deficits in eyes with ischemic RVOs. LSFG findings also match our understanding of retinal autoregulation, because pure oxygen inhalation significantly decreases ONH MBR in healthy eyes. Finally, two studies have examined the precision and reliability of relative flow volume (RFV) in retinal vessels, another metric generated by the LSFG software, by comparing it with absolute blood flow measurements from laser Doppler velocimetry and Doppler Fourier-domain OCT. In healthy subjects, there is a significant correlation between venous RFV and absolute blood flow.

We hypothesize that LSFG can improve RVO diagnosis and provide useful information to help assess the efficacy of RVO treatment. However, because MBR values are manually collected at the researcher’s discretion from the ONH, choroid, or specific retinal vessels, it is difficult to compare findings between studies. Analyses are additionally complicated by significant intersubject heterogeneity that goes beyond simple demographic differences. Therefore the first aim of this study is to define a novel metric—relative blood flow (RBF)—and demonstrate how it effectively describes the impediment of retinal blood flow in patients with unilateral RVO. The second aim of this study is to compare this metric to known characteristics of RVOs and use it to help predict future outcomes.

Methods

Study Design

This study was a prospective, exploratory analysis of retinal blood flow in patients with retinal vein occlusions.

Participants

The study cohort included 20 control subjects with no ocular conditions or systemic diseases. The experimental cohort consisted of 15 subjects with unilateral CRVO and 17 subjects with unilateral BRVO diagnosed by Beth Israel Deaconess Medical Center’s retina services. Patients who had any additional macula-involving disease in either eye, media opacities, or recent (<3 month) history of injections, lasers, or surgery were excluded.

Data Collection

We used LSFG-NAVI (Softcare Co., Ltd., Fukuoka, Japan) to measure dynamics retinal circulation. This imaging technology has been used in numerous studies as a robust method of measuring and quantifying ocular blood flow. The system consists of a fundus camera and laser. The laser, which is scattered by erythrocytes traveling through retinal vessels, creates an interference pattern that is subsequently captured by a Charge-coupled Device (CCD) video camera. Softcare software can then be used to mark an area of interest, typically an ellipse around the ONH. By comparing frame-by-frame measurements over the course of a subject’s heartbeat, an arbitrary MBR unit can be calculated as a measure of blood flow. More detailed descriptions of this protocol have been described elsewhere. Measurements for both eyes were taken in triplicate for each subject. For each eye, an ellipse rubber band was created to cover the entire ONH. For each measurement of a single eye, the rubber band was automatically placed in the same location to ensure consistency. For each rubber band, the MV – MT MBR measurement was used, which removes the mean MBR of the tissue area from the mean MBR of the vascular area.

Although Softcare Co has codified terminology in their manual, we chose to create our own for clarity and specificity (Fig. 1). “Frame MBR” was the instantaneous MBR value obtained in each frame of the measure. These frame MBRs were averaged over
the course of a subject’s heartbeat to calculate the “heartbeat MBR,” the most basic unit of measure and the output of a single LSFG-NAVI video image. The three measurements in each eye were then averaged to obtain a single eye MBR that could be used for comparisons between eyes and to estimate measurement error. Finally, a subject’s RBF was calculated by dividing their diseased eye’s average MBR by their fellow unaffected eye’s average MBR or, in the case of healthy controls, their average left eye MBR by their average right eye MBR. This ratio is our primary metric and is unitless. Therefore an RBF of 0.70 in a CRVO patient indicates that their CRVO eye has 70% of the blood flow in their unaffected fellow eye.

Demographics Variables and Disease Characteristics

Through medical chart review, we identified sex, race, diabetes, hypertension, and high cholesterol status as general demographic variables that put our new metric in context. We also evaluated whether patients had glaucoma, cataract, a posterior chamber intraocular lens, and, in the diseased eye only, epiretinal membrane or neovascularization of the optic disk. We subdivided BRVO patients on the basis of the location of their occlusion—superior or inferior—and calculated duration of RVO as the time between first diagnosis and measurement of blood flow. Before the blood flow measurement, we determined whether
patients had received surgery, injection, or laser treatment on either eye. After the measurement, we identified patients who were prescribed or received injection within three months of that date. Total number of injections takes into account all injections the patient received for RVO, both before and after the measurement. Finally, we examined central macular thickness (CMT), intraocular pressure (IOP), and best-corrected visual acuity at the time of blood flow measurement (month zero) and repeated these measurements one and three months later on a subset of patients. CMT was measured on an OCT Spectralis (Heidelberg Engineering, Heidelberg, Germany) and IOP was measured using a Tono-Pen (Reichert Inc., Depew, New York, USA).

Statistical Analyses

Initial analysis consisted of analysis of variance tests to explore the consistency of MBR between control eyes and the reliability of our consistency assumption. The primary analysis consisted of a Welch’s t-test between the RBF of CRVO and BRVO eyes to healthy controls. We then performed a series of univariate analyses between demographic variables and disease characteristics to confirm that our metric matches the current understanding of RVOs. Finally, to determine whether RBF was useful in predicting the need for an injection within the next three months, we created a logistic regression model using RVO duration, CMT at time of imaging, and RBF as predictors. The significance of model coefficients and predictive power in the form of both qualitative descriptions and optimism-adjusted bootstrapped C-statistics from the logistic regression model were analyzed. All descriptive statistics were created using SPSS (IBM Co., Armonk, NY, USA). Calculations of RBF and all related analyses and graphs were generated using R statistical software (version 3.5.2, R Core Team, Vienna, Austria). The institutional review board at Beth Israel Deaconess Medical Center authorized this study, all patients provided informed consent, and research was conducted in accordance with the Declaration of Helsinki.

Results

Blood Flow in Healthy Eyes

While heartbeat MBR varied between subjects (F_{19} = 14.60, P < .001, Fig. 2), there was no statistically significant difference between the eyes of a single control subject (F_{1} = 0.83, P = 0.37) or in repeated imaging sessions (F_{1} = 0.012, P = 0.91). Thus, the heartbeat MBR measurement is consistent between images and eyes of a single patient but not between patients. We then calculated the RBF of healthy eyes for use as a comparison group (mean ± SD = 1 ± 0.01, Fig. 3, blue box).

Blood Flow in Eyes With Unilateral RVO

We examined the blood flow in patients with unilateral CRVO or BRVO. Patients with both CRVO (n = 15, mean ± SD = 0.74 ± 0.05, P < .001) and BRVO (n = 17, mean ± SD = 0.93 ± 0.05, P = 0.015) had lower RBF than our healthy patients (Fig. 3, red and green boxes). Thus there was an average reduction in blood flow of 30% in eyes with CRVOs and
Relative Retinal Blood Flow

Figure 4. Comparison of MBR between eyes. In healthy control subjects, the average single eye MBRs are consistent between both eyes, clustering around the line of equality. In RVO patients, reduction of MBR in the diseased eye places these patients below the line of equality, with CRVO patients showing a more consistent clustering than BRVO patients. For controls, the left eye was taken to be the “RVO Eye.”

9% in eyes with BRVOs. There was, however, substantial heterogeneity within these two groups. In comparing the MBR of the healthy control group eyes to the unaffected eyes in the RVO groups, there was no difference between the control (n = 40, mean = 19.58 ± 1.13) and CRVO groups (n = 15, mean = 18.79 ± 2.09, P = 0.52), but there were lower values in the BRVO group compared to the control group (n = 17, mean = 16.03 ± 1.93, P = 0.004) (Fig. 4).

RBF and Other Factors

We examined the association of a variety of demographic factors, systemic and ocular conditions, treatments, and visual acuity with the relative blood flow (Tables 1, 2, and 3A, 3B). Of the descriptive variables, RVO duration (r = 0.59, P < 0.001), CMT (r = 0.44, P = 0.003), diabetic status (t19 = 3.44, P = 0.003), history of previous laser (t23 = 3.30, P = 0.003), and history of injection treatments (t27 = 2.96, P = 0.006) were positively associated with RBF in CRVO patients (Fig. 5). Need for injection within three months (r = −2.61, P = 0.013) and IOP (r = −0.34, P = 0.029) were negatively associated with RBF in CRVO patients (Fig. 5). No descriptive variables were significantly associated with BRVO patients. Excluding four subjects with glaucoma did not significantly change RBF findings for the CRVO (mean = 0.75, t102 = 0.48, P = 0.63) or BRVO (mean = 0.92, t66 = 0.12, P = 0.90) groups.

Table 1. Patient Demographics

|                     | CRVO | BRVO | RVO Total | Control |
|---------------------|------|------|-----------|---------|
| Eye                 |      |      |           |         |
| Left                | 8 (53.3) | 7 (41.2) | 15 (46.9) | —       |
| Right               | 7 (46.7) | 10 (58.8) | 17 (53.1) | —       |
| Total               | 15 | 17 | 32 (100) | —       |
| Sex                 |      |      |           |         |
| Female              | 6 (40) | 12 (70.6) | 18 (56.3) | 13 (65) |
| Male                | 9 (60) | 5 (29.4) | 14 (43.8) | 7 (35)  |
| Age, Mean (yrs)     | 62 | 74 | 68 | 37 |
| PCIOl               |      |      |           |         |
| Disease eye         | 3 (20) | 8 (47.1) | 11 (34.4) | —       |
| Fellow eye          | 3 (20) | 5 (29) | 8 (25) | —       |
| RVO eye—Other Disease | 2 (13.3) | 2 (11.8) | 4 (12.5) | —       |
| Epi retinal membrane | 0 (0) | 0 (0) | 0 (0) | —       |
| Neovascularization of the disk | 8 (53.3) | 12 (70.6) | 20 (62.5) | —       |
| Hypertension        | 4 (26.7) | 6 (35.3) | 10 (31.3) | —       |
| Diabetes            | 6 (40) | 8 (47.1) | 26 (59.4) | —       |
| Cataract            | 2 (13.3) | 2 (11.8) | 4 (12.5) | —       |
| Glaucoma            | 5 (33.3) | 4 (23.5) | 9 (28.1) | 0 (0)   |
| High cholesterol    | 5 (33.3) | 8 (47.1) | 13 (40.6) | 0 (0)   |
| No                  | 5 (33.3) | 5 (29.4) | 10 (31.3) | 20 (100) |
| Not specified       | 5 (33.3) | 4 (23.5) | 9 (28.1) | 0 (0)   |
| Race                |      |      |           |         |
| Asian               | 2 (13.3) | 1 (5.9) | 3 (9.4) | 7 (35)  |
| Black/African       | 3 (20) | 5 (29.4) | 8 (25) | 1 (5)   |
| Hispanic            | 1 (6.7) | 3 (17.7) | 4 (12.5) | 4 (20)  |
| White               | 7 (46.7) | 8 (47.1) | 15 (46.9) | 8 (40)  |
| Not specified       | 2 (13.3) | 0 (0) | 2 (6.3) | 0 (0)   |
| BRVO type           |      |      |           |         |
| Superior            | — | 5 (29.4) | — | —       |
| Inferior            | — | 8 (47.1) | — | —       |
| Not specified       | — | 4 (23.5) | — | —       |
| Total               | — | 17 (100) | — | —       |
| Prior surgery       |      |      |           |         |
| Disease eye         | 3 (20) | 8 (47.1) | 11 (34.4) | —       |
| Fellow eye          | 3 (20) | 4 (23.5) | 7 (21.9) | —       |
| Prior laser         |      |      |           |         |
| Disease eye         | 12 (80) | 16 (94.1) | 28 (87.5) | —       |
| Fellow eye          | 1 (6.7) | — | 1 (3.1) | —       |
| Prior injection     |      |      |           |         |
| Disease eye         | 11 (73.3) | 14 (82.4) | 25 (78.1) | —       |
| Fellow eye          | 0 (0) | 0 (0) | 0 (0) | —       |
| Injection within 3 months | 6 (40) | 5 (29.4) | 11 (34.4) | —       |
| Duration of RVO (mos) |      |      |           |         |
| Mean                | 35.50 (3.0) | 44.82 (3.7) | 40.61 (3.4) | —       |
| Median              | 25.50 (2.1) | 36 | 31 | —       |
| SD                  | 35.90 (3.0) | 32.28 (2.7) | 33.70 (2.8) | —       |
| Range               | 120 | 118 | 121 | —       |
| Min                 | 0 | 3 | 0 | —       |
| Max                 | 120 | 121 | 121 | —       |
| Total number of injections |      |      |           |         |
| Mean                | 8.13 | 5.41 | 6.69 | —       |
| Median              | 9 | 4 | 5 | —       |
| SD                  | 7.1 | 5.17 | 6.2 | —       |
| Range               | 20 | 20 | 20 | —       |
| Min                 | 0 | 0 | 0 | —       |
| Max                 | 20 | 20 | 20 | —       |

Max, maximum; Min, minimum; PICOL, posterior chamber intraocular lens.
In subjects with CRVO, RBF had significant predictive power of need for injection within three months, independent of that visit’s CMT and RVO duration (Table 4). Among six subjects who had CMT in normal ranges, three subjects had RBF < 0.60 (0.30, 0.57, 0.57), whereas the other three had RBF > 0.75 (0.86, 0.80, 0.76). Those with RBF < 0.60 needed an injection in three months, whereas those with RBF > 0.75 did not. We also observed the predictive power of RBF quantitatively in our optimism-adjusted bootstrapped c-statistics in models: RVO duration and CMT without RBF (0.80) differed from RVO duration and CMT with RBF (0.85) (Fig. 6). This means the model can correctly predict the need for injections within three months 80% of the time using RVO duration and CMT alone and 85% of the time if RBF is used as well.

Discussion

Relative blood flow, the extent to which the blood flow in an eye is compromised by a retinal vein occlusion compared to the blood flow in the unaffected fellow eye, represents a promising new and informative metric for quantifying the severity of unilateral retinal vein occlusions at a single time point. In this study, we first demonstrated the consistency of blood flow between a healthy subject’s eyes and observed decreased blood flow in eyes with retinal diseases before using this knowledge to consider a patient’s fellow eye as a healthy expectation of their diseased eye. By finding the unitless ratio between a single patient’s eyes, we then measured the extent to which the RVO impedes blood flow in the form of relative blood flow. Finally, we found associations between RBF and established descriptive variables and used it as an independent predictor of a patient’s need for injection in the next three months.

Our novel RBF measure has substantial advantages over previously used metrics. Although previous studies use LSFG to evaluate changes to retinal blood flow in eyes with RVO, there is a lack of consensus on how best to analyze and interpret various MBR values within and between patients. Many studies are unable to interpret MBR values collected from one session and rely on MBR ratios generated over
Table 3A. Test Statistics, Correlations, and P Values Comparing RBF and Demographic Variables in RVOs

|                | CRVO RBF |              | BRVO RBF |              |
|----------------|----------|--------------|----------|--------------|
|                | t Statistic | df  | P Value | t Statistic | df  | P Value |
| Phakic status  | −1.28    | 10  | 0.23    | −0.219     | 24  | 0.83    |
| Cataract       | 1.52     | 13  | 0.15    | 0.37       | 22  | 0.72    |
| Glaucoma       | −1.56    | 5   | 0.18    | −1.39      | 7   | 0.21    |
| High cholesterol | −0.41  | 22  | 0.69    | −0.57      | 14  | 0.58    |
| Hypertension   | 0.71     | 38  | 0.48    | 0.47       | 8   | 0.65    |
| Diabetes       | 3.44     | 19  | **0.0028** | 0.96     | 20  | 0.35    |
| Previous laser | 3.30     | 23  | **0.0032** | −0.96     | 3   | 0.42    |
| Previous injection | 2.96  | 27  | **0.0064** | −0.34     | 9   | 0.74    |
| Injection within 3 months after blood flow measurement | −2.61 | 33  | **0.013** | −0.56 | 14  | 0.58    |

Statistically significant values (P < .05) are bold.

Table 3B. Test Statistics, Correlations, and P Values Comparing RBF and Demographic Variables in RVOs

|                | Correlation Coefficient | P Value | Correlation Coefficient | P Value |
|----------------|-------------------------|---------|-------------------------|---------|
| Age            | 0.16                    | 0.31    | −0.28                   | 0.15    |
| RVO duration   | 0.59                    | <0.001  | 0.17                    | 0.40    |
| CMT (Month 0)  | 0.44                    | **0.0034** | −0.28              | 0.15    |
| IOP (Month 0)  | −0.34                   | 0.029   | −0.26                   | 0.29    |
| BCVA (Month 0) | −0.03                   | 0.84    | −0.29                   | 0.14    |
| Total injection | 0.20                    | 0.21    | −0.19                   | 0.33    |

Statistically significant values (P < .05) are bold.
BCVA, best-corrected visual acuity.

Table 4. Predictive Power of RBF on Need for Injection Within the Next Three Months

|                                | Coefficient | SE    | P Value |
|--------------------------------|-------------|-------|---------|
| Central macular thickness (month 0) | 0.017      | 0.007 | 0.013   |
| RVO duration                   | −0.037      | 0.017 | 0.032   |
| Relative blood flow            | −7.49       | 2.99  | 0.018   |
| Optimism-adjusted bootstrapped C-statistic |          |       |         |
| Duration + CMT                 | 0.80        |       |         |
| Duration + CMT + RBF           | 0.85        |       |         |

Analysis of coefficients and c-statistic of logistic regression model.

Furthermore, RFV is reliable only when examining venous flow, but heterogeneity between the vasculature of a patient’s eyes, as well as between the eyes of many patients, limit the practicality of this measure. RBF is an intuitive, unitless metric that can be collected in one session and, in theory, be applied to any empirical measure of retinal blood flow, not just the LSFG.

RBF appears to be more useful in describing CRVOs than BRVOs. This is primarily because CRVOs impede blood flow around the entire optic nerve, whereas BRVOs only affect blood flow around part of the nerve (30% reduction as opposed to 9% reduction). CRVO RBF also correlates with multiple descriptive factors and predicts need for future injections, whereas BRVO RBF does not. As such, we will primarily be discussing the implications of CRVO RBF here.

RBF correlates with a variety of descriptive characteristics of CRVOs. Older RVOs and those with previous treatments had less obstructed blood flow,
Figure 5. Correlations between relative blood flow and covariates in eyes with CRVO and BRVO. A heat map of the correlations between the continuous covariates and outcomes. Red cells indicate positive correlations, whereas blue indicate negative correlations. The intensity of the color indicates the strength of the correlation.

Figure 6. Predictive power of logistic regression model with and without the novel RBF metric. Relative blood flow added significant predictive power to a logistic regression model predicting need for injection within three months of measurement in patients with CRVO. This power was in addition to (and thus independent of) central macular thickness and the duration of time since the onset of patients’ symptoms. Thus RBF adds new and important information that a clinician may wish to use while evaluating patients with this condition.

consistent with the idea that laser or injection treatments may help improve perfusion and that the retinal vascular occlusion recannulates or develops collateral vessels, reducing resistance over time. Our findings appear to confirm two recent studies that find a correlation between intravitreal injection and subsequent increase in blood flow. Subjects with diabetes had greater (more normal) RBF than those without, although it is notable that these patients had no history of diabetic retinopathy. This finding is consistent with previous reports that patients with diabetes but no retinopathy have increased retinal blood flow compared to healthy controls. Finally, CMT was positively correlated with RBF, indicating that subjects with a significant amount of edema actually have fairly normal blood flow. We do not believe that macular edema interfered with data quality, because our images and data were collected from the ONH area, not the macular area. For a similar reason, we do not believe that the presence of an epiretinal membrane should interfere with RBF measurement at the ONH, consistent with previous studies comparing LSFG measurements before and after vitrectomies.

It has long been known that RVOs result in reduced retinal perfusion, but they are generally described in terms of the related symptoms (such as macular edema and CMT, tortuosity of blood vessels, and presence of nonperfusion)—rather than as a direct, quantitative measurement of the blood flow. In general, qualitative, symptom-based characterization is adequate, and outcomes can often be quite good after treatment. However, there are opportunities for additional data to be clinically useful. Current treatment protocols rely heavily on clinician intuition, and it is not always clear when to transition patients from monthly schedules and how frequently injections should be administered after symptoms have diminished. Our RBF measure, which aids in predicting need for anti-Vascular Endothelial Growth Factor (VEGF) injections independently of from RVO duration and CMT, could help to inform treatment strategies and perhaps decrease the frequency of injections required for effective RVO management.

In our patients, we found that there was no difference in the MBR of the unaffected CRVO eyes when compared to the control group, but that the MBR of unaffected BRVO eyes was significantly lower. This difference is most likely explained by the higher age of BRVO patients when compared to the other groups and the well-documented finding that MBR decreases with age. Notably, there was no correlation between RBF and age in either group, indicating that the metric is associated with disease-related differences rather than demographic
changes. Age-related changes to MBR also highlight why it is useful to use the intrapatient control of patient’s fellow eye when making comparisons of blood flow.

This study has several limitations. First, the sample size was relatively small and may be ungeneralizable and underpowered to detect small differences or to perform subgroup analyses. Our recruitment base was fairly small, and labor-intensive data collection exacerbated patient recruitment, which may be an issue for this device’s practical utility. Second, the RBF metric cannot be used on patients with bilateral retinal disease, because it relies on a patient’s unaffected fellow eye as an internal control. Third, like all imaging devices, LSFG was less effective on patients with media opacities or who had difficultyfixating their vision. Fourth, we only collected and analyzed blood flow data from the entire ONH area of the retina. Changes to relative blood flow in certain quadrants of the ONH area, or other regions of the retina, were not examined but may also be informative, especially in BRVO. Because our metric is unitless, other imaging techniques that capture blood flow in different areas should be able to use RBF to expand our findings. Fifth, arterial blood pressure and ocular perfusion pressure were not obtained, because RBF values were calculated within each patient at one time point. It is possible that significant differences in IOP between the eyes of a patient may affect RBF; however, a previous study only noted significant changes in MBR at the ONH when IOP was increased by 20 mm Hg. The average IOP difference between eyes for our patients was 1.6 mm Hg, with the highest difference being 6 mm Hg. Previous studies show no significant correlation between LSFG indices and mean arterial pressure or ocular perfusion pressure. Finally, the limited timeframe of this study impeded our ability to collect the full range of longitudinal data.

In this exploratory study, we were able to validate LSFG as a reliable technology for the measure of intrapatient retinal blood flow and created a new metric of retinal vein occlusion severity, relative blood flow. We used this measure to quantify the decreased blood flow in eyes with retinal vein occlusion. We found significant associations between relative blood flow in CRVO and diabetes, previous laser, previous injection, need for injection within three months of blood flow measurement, duration of occlusion, central macular thickness, and intraocular pressure. Future studies may further elucidate these findings—in particular, studies should assess whether relative blood flow can be used as a predictive factor for whether a patient will need an injection in the next three months and explore this metric in other imaging devices, such as OCTA. As a severity metric for retinal vein occlusion, relative blood flow may add depth to diagnoses and streamline treatment plans for patients with retinal vein occlusion.

Acknowledgments

Disclosure: R. Koch, None; B. Seto, None; K. Yamada, None; P. Atreay, None; C.A. Lemire, None; N. Hazra, None; J.G. Arroyo, None

References

1. Song P, Xu Y, Zha M, Zhang Y, Rudan I. Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors. J Global Health. 2019;9(1):010427.
2. Wong TY, Scott IU. Retinal-Vein Occlusion. N Engl J Med. 2010;363(22):2135–2144.
3. Iijima H. Mechanisms of vision loss in eyes with macular edema associated with retinal vein occlusion. Jpn J Ophthalmol. 2018;62(3):265–273.
4. Osamura H, Shiba T, Itokawa T, Matsumoto T, Hori Y. Relationships among ocular blood flow shown by laser speckle flowgraphy, retinal arteriosclerotic change, and chorioretinal circulation time obtained by fluorescein angiography. J Ophthalmol. 2017;2017:1–7.
5. Tsai G, Banaee T, Conti F, Singh R. Optical coherence tomography angiography in eyes with retinal vein occlusion. J Ophthalmic Vis Res. 2018;13(3):315.
6. Matsumoto M, Suzuma K, Yamada Y, Tsuiki E, Fujikawa A, Kitaoka T. Retinal blood flow after intravitreal bevacizumab is a predictive factor for outcomes of macular edema associated with central retinal vein occlusion. Retina. 2018;38(2):283–291.
7. Eydelman MB. 510(k) for laser speckle flowgraphy: substantial equivalence determination. Published online May 12, 2016, https://www.accessdata.fda.gov/cdrh_docs/pdf15/K153239.pdf. Accessed June 11, 2020.
8. Iwase T, Ra E, Yamamoto K, Kaneko H, Ito Y, Terasaki H. Differences of retinal blood flow between arteries and veins determined by laser speckle flowgraphy in healthy subjects: Medicine. 2015;94(33):e1256.
9. Shiga Y, Asano T, Kunikata H, et al. Relative flow volume, a novel blood flow index in the human
retina derived from laser speckle flowgraphy. *Invest Ophthalmol Vis Sci* 2014;55(6):3899.

10. Willerslev A, Li XQ, Munck IC, Larsen M. Relation between fluorescein angiographic and spectral-domain optical coherence tomography findings of blood flow turbulence at arteriovenous crossings in the retina. *Retin Cases Brief Rep*. 2019;13(1):61–66.

11. Riva CE, Grunwald JE, Sinclair SH, Perrig BL. Blood Velocity and Volumetric Flow Rate in Human Retinal Vessels. *Invest Ophthalmol Vis Sci*. 1985;26(8):1124–1132.

12. Garhofer G, Werkmeister R, Dragostinoff N, Schmetterer L. Retinal blood flow in healthy young subjects. *Invest Ophthalmol Vis Sci*. 2012;53(2):698.

13. Luft N, Wozniak PA, Aschinger GC, et al. Measurements of retinal perfusion using laser speckle flowgraphy and Doppler optical coherence tomography. *Invest Ophthalmol Vis Sci*. 2016;57(13):5417.

14. Petrig BL, Riva CE, Hayreh SS. Laser Doppler flowmetry and optic nerve head blood flow. *Am J Ophthalmol*. 1985;124(7):413–425.

15. Kakihara S, Hirano T, Iesato Y, Imai A, Toriyama Y, Murata T. Extended field imaging using swept-source optical coherence tomography angiography in retinal vein occlusion. *Jpn J Ophthalmol*. 2018;62(3):274–279.

16. Moussa M, Leila M, Bessa AS, et al. Grading of macular perfusion in retinal vein occlusion using en-face swept-source optical coherence tomography angiography: a retrospective observational case series. *BMC Ophthalmol*. 2019;19(1):127.

17. Tsuboi K, Kamei M. Longitudinal vasculature changes in branch retinal vein occlusion with projection-resolved optical coherence tomography angiography. *Graefes Arch Clin Exp Ophthalmol*. 2019;257(9):1831–1840.

18. Shiraki A, Sakimoto S, Tsuboi K, et al. Evaluation of retinal nonperfusion in branch retinal vein occlusion using wide-field optical coherence tomography angiography. *Acta Ophthalmologica*. 2019;97(6):e913–e918.

19. Aharony O, Gal-Or O, Polat A, Nahum Y, Weinberger D, Zimmer Y. Automatic characterization of retinal blood flow using OCT angiograms. *Transl Vis Sci Technol*. 2019;8(4):6.

20. Werner JU, Böhm F, Lang GE, Dreyhaupt J, Lang GK, Enders C. Comparison of foveal avascular zone between optical coherence tomography angiography and fluorescein angiography in patients with retinal vein occlusion. * Yi J, ed. PLOS ONE*. 2019;14(6):e0217849.

21. Shin Y-I, Nam KY, Lee SE, et al. Changes in peripapillary microvasculature and retinal thickness in the fellow eyes of patients with unilateral retinal vein occlusion: an OCTA study. *Invest Ophthalmol Vis Sci*. 2019;60(2):823.

22. Freund KB, Sarraf D, Leong BCS, Garrity ST, Vupparaboina KK, Dansingani KK. Association of optical coherence tomography angiography of collaterals in retinal vein occlusion with major venous outflow through the deep vascular complex. *JAMA Ophthalmol*. 2018;136(11):1262.

23. Tsuda S, Kunikata H, Shimura M, et al. Pulse-waveform analysis of normal population using laser speckle flowgraphy. *Curr Eye Res*. 2014;39(12):1207–1215.

24. Yamada Y, Suzuma K, Matsumoto M, et al. Retinal blood flow correlates to aqueous vascular endothelial growth factor in central retinal vein occlusion. *Retina*. 2015;35(10):2037–2042.

25. Noma H, Yasuda K, Minezaki T, Watarai S, Shimura M. Changes of retinal flow volume after intravitreal injection of bevacizumab in branch retinal vein occlusion with macular edema: a case series. *BMC Ophthalmol*. 2016;16(1):61.

26. Shiga Y, Sato M, Maruyama K, et al. Assessment of short-term changes in optic nerve head hemodynamics in hyperoxic conditions with laser speckle flowgraphy. *Curr Eye Res*. 2015;40(10):1055–1062.

27. Kobayashi T, Shiba T, Kinoshita A, Matsumoto T, Hori Y. The influences of gender and aging on optic nerve head microcirculation in healthy adults. *Sci Rep*. 2019;9(1):15636.

28. Kobayashi T, Shiba T, Nishiwaki Y, Kinoshita A, Matsumoto T, Hori Y. Influence of age and gender on the pulse waveform in optic nerve head circulation in healthy men and women. *Sci Rep*. 2019;9(1):17895.

29. Sugiyama T, Araie M, Riva CE, Schmetterer L, Orgul S. Use of laser speckle flowgraphy in ocular blood flow research. *Acta Ophthalmol*. 2010;88(7):723–729.

30. Smith GCS, Seaman SR, Wood AM, Royston P, White IR. Correcting for optimistic prediction in small data sets. *American Journal of Epidemiology*. 2014;180(3):318–324, doi:10.1093/aje/kwu140.

31. Kunikata H, Nitta F, Aizawa N, et al. The effect of intravitreal bevacizumab on ocular blood flow in diabetic retinopathy and branch retinal vein occlusion as measured by laser speckle flowgraphy. *Clin Ophthalmol*. 2014;8:1119–1127.

32. Nagaoka T, Sogawa K, Yoshida A. Changes in retinal blood flow in patients with macular edema secondary to branch retinal vein occlusion before
and after intravitreal injection of bevacizumab. *Retina*. 2014;34(10):2037–2043.

33. Nagasato D, Mitamura Y, Semba K, et al. Correlation between optic nerve head circulation and visual function before and after anti-VEGF therapy for central retinal vein occlusion: prospective, interventional case series. *BMC Ophthalmol*. 2016;16(1):36.

34. Palochak CMA, Lee HE, Song J, et al. Retinal blood velocity and flow in early diabetes and diabetic retinopathy using adaptive optics scanning laser ophthalmoscopy. *J Clin Med*. 2019;8(8):1165.

35. Iwase T, Kobayashi M, Yamamoto K, Yanagida K, Ra E, Terasaki H. Changes in blood flow on optic nerve head after vitrectomy for rhegmatogenous retinal detachment. *Invest Ophthalmol Vis Sci*. 2016;57(14):6223–6233.

36. Okamoto M, Matsuura T, Ogata N. Ocular blood flow before, during, and after vitrectomy determined by laser speckle flowgraphy. *Ophthalmic Surg Lasers Imaging Retina*. 2014;45(2):118–124.

37. Spooner K, Fraser-Bell S, Hong T, Chang AA. Five-year outcomes of retinal vein occlusion treated with vascular endothelial growth factor inhibitors. *BMJ Open Ophthalmol*. 2019;4(1):e000249.

38. Lashay A, Riazi-Esfahani H, Mirghorbani M, Yaseri M. Intravitreal Medications for Retinal Vein Occlusion: Systematic Review and Meta-analysis. *J Ophthalmic Vis Res*. 2019;4(1):e000249.

39. Osaka R, Muraoka Y, Miwa Y, et al. Anti-vascular endothelial growth factor therapy for macular edema following central retinal vein occlusion: 1 initial injection versus 3 monthly injections. *Ophthalmologica*. 2018;239(1):27–35.

40. Kobayashi T, Shiba T, Kinoshita A, Matsumoto T, Hori Y. The influences of gender and aging on optic nerve head microcirculation in healthy adults. *Sci Rep*. 2019;9(1):15636.

41. Kiyota N, Shiga Y, Ichinohasama K, et al. The impact of intraocular pressure elevation on optic nerve head and choroidal blood flow. *Invest Ophthalmol Vis Sci*. 2018;59(8):3488.